Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Although there was a similar HR for superior survival with AA plus prednisone in the visceral disease group, this difference did not reach statistical significance due to the much smaller sample size (HR=0.79; 95% CI: 0.60–1.05; P =0.102) ( Figure 1a ).

also in 111,027 other papers